We are developing drugs based on two uniquely different approaches.

The first approach targets tumor hypoxia, which is a common characteristic of the tumor microenvironment and is associated with tumor progression, metastasis, resistance to radiotherapy and standard chemotherapy, and ultimately treatment failure. Threshold’s lead product candidate, evofosfamide, is a prodrug that is selectively activated under hypoxic conditions.

Threshold is also targeting cancers that overexpress high levels of an enzyme called aldo-keto reductase 1C3 (AKR1C3). AKR1C3 is a steroidogenic enzyme that is implicated in the development of various tumors, including liver cancer (HCC), castration-resistant prostate cancer (CRPC) and T-cell acute leukemias (T-ALL).